A November 2023 label change added new Syfovre warnings for retinal vascular occlusion and retinal vasculitis cases associated with Syfovre injections. With these new Syfovre warnings, it now seems that the retinal vascular occlusion and retinal vasculitis cases associated with Syfovre use are due to the drug itself and not the injection kits, as had been suggested by Apellis Pharmaceuticals.
Just a few months ago, in August 2023, Apellis suggested that an issue related to certain injection kits used for Syfovre may be a possible cause of the retinal vascular occlusion and retinal vasculitis cases associated with Syfovre use. And back then Apellis had urged doctors to switch to a different injection kit.
We have been writing about Syfovre drug safety developments having to do with retinal vascular occlusion and retinal vasculitis cases as well as other eye-related Syfovre side effects since July 2023. Here is a list of our earlier Drug Injury Watch articles:
Syfovre Patients Eye Side Effects Cases at Iowa Clinic: Important 2023 AAO Meeting Presentation [11/10/2023]
Apellis Updates Number of Syfovre Retinal Vasculitis Cases But Provides No Further “Explanation” [10/13/2023]
Syfovre Adverse Reaction Cases: Updated Number of Patients With Retinal Vasculitis, Timeline of Events [8/17/2023]
Syfovre Retinal Vasculitis And Severe Intraocular Inflammation Cases Reported By Ophthalmologists [7/28/2023]
Eye Drug Syfovre Side Effects: Occlusive Retinal Vasculitis, Eye Inflammation, Vision Loss, And Blindness [7/19/2023]
We are investigating Syfovre drug injury lawsuits that would be filed against Apellis Pharmaceuticals for patients involving retinal vascular occlusion and retinal vasculitis cases as well as other eye-related Syfovre side effects. The new Syfovre warnings added in November 2023 should be a positive factor in these Syfovre lawsuits. Please do not hesitate to contact us for a Free Syfovre Case Evaluation.
[View article at original source]Syfovre
Free Case Evaluation
Strictly Confidential, No Obligation